# Speciality European Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/speciality-european-pharma

- Industry: Pharmaceuticals
- Headquarters: London, UK
- Website: www.specialityeuropeanpharma.com
- Total disclosed funding: $43M
- Latest round: Series B (Aug 1, 2008)
- Investors on record: 3

## About

Speciality European Pharma Limited is a pharmaceutical company focused on developing and providing specialty medicines tailored to meet specific medical needs, particularly in complex health areas and rare diseases.Speciality European Pharma Limited operates in the pharmaceutical sector, concentrating on specialty medications. Founded in 2006 and headquartered in London, UK, the company has engaged in six deals to date, with its most recent funding round being a GROWTH investment of GBP 4.75 mn from Beringea Private Equity on January 14, 2015. The company has been strategically positioned without any referenced changes in business operations or ownership structure. Patrick Banks serves as the CEO.Speciality European Pharma focuses on providing a range of pharmaceutical products dedicated to addressing specific medical needs within various therapeutic areas. The company's core offerings include specialty medicines designed for conditions requiring targeted medical interventions, such as rare diseases and complex health concerns. These products enhance patient outcomes by offering innovative treatment options that are not widely available in conventional healthcare settings. The company serves a diverse client base, including healthcare providers, hospitals, and specialty pharmacies across European markets, particularly in the United Kingdom, Germany, and France.In 2022, Speciality European Pharma reported a revenue of GBP 18,145,413.10 and an EBITDA of GBP 11,939,688.80. The company primarily generates revenue through direct sales to healthcare institutions and specialty pharmacies, operating within a B2B model. Transactions typically involve the procurement of specialty pharmaceuticals under negotiated contracts, which may include volume-based pricing agreements. The company has engaged in partnerships with healthcare providers to enhance distribution and access to its flagship products.Speciality European Pharma aims to expand its product offerings by developing new specialty medicines tailored to market needs, with anticipated launches in the coming years. The company is also focusing on expanding into new geographic regions, specifically targeting markets in Eastern Europe by 2024. The recent GROWTH funding of GBP 4.75 mn will be utilized to support these initiatives, including product development and market entry strategies, enhancing the company’s capacity to meet emerging healthcare demands.

## Funding rounds

- Series B, Aug 1, 2008, $24M — Merifin Capital, BSI Bank, Advent Life Sciences
- Series A, Feb 5, 2007, $20M — Advent Life Sciences
- Seed, Sep 14, 2006 — Advent Life Sciences

## Investors

- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Seed, Series A, Series B
- Merifin Capital (https://capitalatlas.ai/funds/merifin-capital) — Series B
- BSI Bank — Series B